[This Week's IPO] Book-Building and Subscription Schedule for the First Week of July View original image

In the first week of July, HL Genomics will conduct a book-building process for institutional investors. Remedi is preparing for its public subscription for individual investors.


<Book-Building>


◆HL Genomics = Founded in 2000, this company specializes in active pharmaceutical ingredients (APIs), producing high-quality APIs that serve as the main ingredients for finished pharmaceutical products. The company has built a portfolio of APIs focused on chronic diseases, including cardiovascular, respiratory, musculoskeletal, and neurological areas, based on its high-purity crystallization and impurity control technologies.


The total number of shares to be offered is 2,565,000, and the anticipated offering price band is between 18,500 won and 21,500 won. Based on this, the expected total amount to be raised ranges from 47.5 billion won to 55.1 billion won. The book-building for institutional investors will take place from July 2 to July 8, and the public subscription for individual investors will be held from July 13 to July 14. KB Securities and IBK Investment & Securities are serving as joint underwriters.


<Public Subscription>


◆Remedi = The offering price has been set at the top end of the anticipated price band, 20,700 won. A total of 2,246 domestic and overseas institutional investors participated in the book-building, resulting in a competition ratio of 1,146 to 1. The public subscription for individual investors will be conducted over two days, July 1 and July 2, and the company is scheduled to list on the KOSDAQ market on July 13. KB Securities is the lead underwriter.



Remedi is a company that has developed and commercialized medical handheld X-ray devices, industrial non-destructive testing equipment, and core X-ray components, based on its proprietary low-dose, miniaturized, and high-definition X-ray technology. The company has established a full-stack technology system that enables it to develop everything from core components to finished products in-house, allowing it to rapidly expand its business into medical, industrial, and special-purpose markets.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing